The Resource for your Nonhuman Primate Research

We support innovation, reproducibility, and translation of preclinical research with high-quality biological development. We offer primate antibodies and recombinant proteins for pre-clinical NHP studies, NHP-specific reagents for in vitro assays, and have an industry wide antibody reactivity database for NHP species.

Our Products

Reactivity Database

Partner With Us

Recent Publications Using Our Reagents...

View All

NHPRR Product Catalog

 

Assay Reagent Catalog

 

New World Monkey Reagents

 

NHPRR Therapeutics Catalog

 

NHPRR News and Announcements

Follow the latest news on NHPRR's LinkedIn account and News Archives

 

NHP Reactivity

💬 Share your thoughts on a new chat-based tool for querying reagents  🚀 

What questions would you want answered?

2026 April 15

a4 Integrin blockade impairs CD8+ T cell neuroimmune surveillance following SIV infection.

Pal, Pabitra B Elizaldi, Sonny R Diniz, Giovanne B Rai, Ravi Prakash Shaan Lakshmanappa, Yashavanth Verma, Anil Rossmiller, Daniel Kaufman, Jesse Srivastava, Rahul Ott, Sean Erices, Carissa T Schwartz, Kayla Beckman, Danielle Ma, Zhong-Min Petkov, Alex Newhouse, Daniel Rajasundaram, Dhivyaa Morrison, John H Raeman, Reben Iyer, Smita S

J Clin Invest

Anti-alpha4/beta7 [A4B7R1] Control antibody rhesus IgG1 (anti-DSP) [DSPR1]

2026 April 01

Development of anti-IgA monoclonal and polyclonal reagents for detecting mucosal and systemic IgA in nonhuman primates.

Iacone, Yasmine Zikos, Joanna Foehl, David Katyal, Priya Gollamudi, Vimala Bibb, Leslie Magnani, Diogo M

J Immunol Methods

Reference rhesus IgG1 Anti-SARS-CoV Spike [CR3022] Goat Anti-Rhesus IgA [GARI]-HRP Goat Anti-Rhesus IgA [GARI] Goat Anti-Rhesus IgA [GARI]-Biotin Control antibody rhesus IgG1 (anti-DSP) [DSPR1] Anti-IgA [NHPMab001]-HRP Anti-IgA [NHPMab001]-Biotin Reference rhesus monomeric IgA [CC6.29] Reference rhesus dimeric IgA [CC6.29]

2026 February 13

Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody development.

Habib, Rumi Roark, Ryan S Li, Hui Connell, Andrew Jesse Hogarty, Michael P Wagh, Kshitij Wang, Shuyi Marchitto, Lorie Skelly, Ashwin N Carey, John W Sowers, Kirsten J Ayyanathan, Kasirajan Plante, Samantha J Bibollet-Ruche, Frederic Park, Younghoon Agostino, Colby J Singh, Ajay Martella, Christian L Lewis, Emily Rando, Juliette M Chohan, Neha Lora, Jinery Ding, Wenge Campion, Mary S Zhao, Chengyan Liu, Weimin Li, Yingying Li, Xuduo Liang, Bo Chowdhury, Rohan Roy Amereh, Khaled Van Itallie, Elizabeth Sheng, Zizhang Ghosh, Amrit R Bar, Katharine J Williams, Wilton B Wiehe, Kevin Saunders, Kevin O Edwards, Robert J Cain, Derek W Lewis, Mark G Batista, Facundo D Burton, Dennis R Andrabi, Raiees Kulp, Daniel W Haynes, Barton F Korber, Bette Shapiro, Lawrence Kwong, Peter D Hahn, Beatrice H Shaw, George M

Sci Immunol

Anti-CD8 beta [CD8b255R1] Anti-CD8 alpha [MT807R1]

2026 January 31

Functional antibody signatures following therapeutic immunization in Simian and Human immunodeficiency virus infection.

Ilan, Shlomi Bartsch, Yannic Jung, Wonyeong Kliuchnikov, Evgenii Roy, Vicky Bonifer, Riley Walker-Sperling, Victoria E K Borducchi, Erica N Nkolola, Joseph P Lauffenburger, Douglas A Stieh, Daniel J Barouch, Dan H Julg, Boris

NPJ Vaccines

Anti-rhesus IgG4 [tessera] Anti-rhesus IgG2 [dio] Anti-rhesus IgG3 [tria] Anti-rhesus IgA [9B9] Anti-rhesus IgG1 [ena]

News & Updates:

View All

2024 Aug 23

mAbsolve Parnership for Fc-silenced STR Antibodies

Today, we celebrate a milestone—partnering with mAbsolve to incorporate ‘STR’ mutations into our antibodies. This ensures targeted action without unintended immune responses, boosting rigor, effectiveness, and safety. By decreasing Fc-mediated interference (hello Fc-block!) and enhancing the signal-to-noise ratio, STR-enhanced antibodies will produce more robust and reproducible scientific findings. Expect many STR-enhanced antibodies soon!

READ MORE

2024 Apr 09

For your Acknowledgements section

Reagents used in these studies were provided by the NIH Nonhuman Primate Reagent Resource (P40 OD028116, U24 AI126683).

2024 Apr 11

NHPRR Linkedin

Follow our newest publications, products, and messages on LinkedIn!

READ MORE

2024 Apr 09

RRID Citation on Materials and Methods

For your Materials & Methods section: The rhesus recombinant Anti-CD8 beta [CD8b255R1] monoclonal antibody was engineered and produced by the Nonhuman Primate Reagent Resource (NIH Nonhuman Primate Reagent Resource Cat# PR-2557, RRID:AB_2716321)

Contribute to the Resource

Help Us By:

Sharing Your Data: Our community-based reactivity database is built by users like you. Share your results!

Requesting a Reagent: We develop NHP-specific antibodies based on investigator-initiated requests, including: recombinant proteins for cell depletion, receptor activation, cytokine neutralization, co-stimulatory blockade, immunosuppression.

Licensing Our Reagents: Interested in using our antibodies on your assays? Reach us!

Sharing Your Publication: If you’ve recently published a study using an NHPRR reagent, add it to the publication database.

The Nonhuman Primate Reagent Resource (NHPRR) is a nonprofit laboratory established in 1999, and supported by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), and Office of Research Infrastructure Programs (ORIP).

Copyright © 2004-2026